Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Homare Eda

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Cancer Treatment and Research|October 4, 2016
Bone Disease in Multiple MyelomaHomare Eda, Loredana Santo, G David Roodman, et al.
Biochemical and Biophysical Research Communications|December 11, 2007
FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cellsHomare Eda, Katsuhiko Aoki, Keishi Marumo, et al.
JBMR Plus|November 18, 2022
TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal OsteopeniaIkuko Ota, Yoshiaki Ota, Kuniaki Ota, et al.
European Journal of Haematology|March 3, 2010
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cellsHomare Eda, Katsuhiko Aoki, Soki Kato, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2014
Role of decorin in multiple myeloma (MM) bone marrow microenvironmentNeeharika Nemani, Loredana Santo, Homare Eda, et al.
International Journal of Oncology|April 11, 2009
Three-dimensional culture using a radial flow bioreactor induces matrix metalloprotease 7-mediated EMT-like process in tumor cells via TGFbeta1/Smad pathwayShun-Ichi Shibata, Hideki Marushima, Tadashi Asakura, et al.
The Journal of Clinical Investigation|March 2, 2016
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancyDongjun Lee, Ying-Hua Wang, Demetrios Kalaitzidis, et al.
International Journal of Oncology|July 26, 2011
Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulationHideki Marushima, Shun-Ichi Shibata, Tadashi Asakura, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 15, 2016
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone DiseaseHomare Eda, Loredana Santo, Marc N Wein, et al.
Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer Treatment and Research|October 4, 2016
Bone Disease in Multiple MyelomaHomare Eda, Loredana Santo, G David Roodman, et al.
Biochemical and Biophysical Research Communications|December 11, 2007
FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cellsHomare Eda, Katsuhiko Aoki, Keishi Marumo, et al.
JBMR Plus|November 18, 2022
TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal OsteopeniaIkuko Ota, Yoshiaki Ota, Kuniaki Ota, et al.
European Journal of Haematology|March 3, 2010
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cellsHomare Eda, Katsuhiko Aoki, Soki Kato, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2014
Role of decorin in multiple myeloma (MM) bone marrow microenvironmentNeeharika Nemani, Loredana Santo, Homare Eda, et al.
International Journal of Oncology|April 11, 2009
Three-dimensional culture using a radial flow bioreactor induces matrix metalloprotease 7-mediated EMT-like process in tumor cells via TGFbeta1/Smad pathwayShun-Ichi Shibata, Hideki Marushima, Tadashi Asakura, et al.
The Journal of Clinical Investigation|March 2, 2016
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancyDongjun Lee, Ying-Hua Wang, Demetrios Kalaitzidis, et al.
International Journal of Oncology|July 26, 2011
Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulationHideki Marushima, Shun-Ichi Shibata, Tadashi Asakura, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 15, 2016
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone DiseaseHomare Eda, Loredana Santo, Marc N Wein, et al.
Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.
Pageof 2